⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
Biocytogen kondigt klinische mijlpaal aan met eerste patiënt die wordt behandeld in fase 1-onderzoek naar IDEAYA's eerste in zijn klasse B7H3/PTK7 bispecifieke TOP1 ADC IDE034
businesswire.com
IDYA
Biocytogen annonce une étape clinique importante avec l'administration du premier traitement à un patient dans le cadre de l'essai de phase 1 sur le TOP1 ADC IDE034, le premier bispécifique B7H3/PTK7 de sa catégorie, développé par IDEAYA
businesswire.com
IDYA
Biocytogen anuncia un hito clínico con el primer paciente que recibe una dosis en el ensayo fase 1 del primer TOP1 ADC IDE034 biespecífico B7H3/PTK7 en su clase de IDEAYA
businesswire.com
IDYA
Biocytogen verkündet klinischen Meilenstein: Erster Patient in Phase-1-Studie von IDEAYAs erstklassigem B7H3/PTK7-bispezifischen TOP1-ADC IDE034 behandelt
businesswire.com
IDYA
百奥赛图宣布达成重要临床里程碑，合作伙伴IDEAYA启动双抗ADC IDE034 I期临床并完成首例患者给药
businesswire.com
IDYA
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
businesswire.com
IDYA
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
businesswire.com
IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
prnewswire.com
IDYA
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
prnewswire.com
IDYA